Ainos Q2 2024 net loss widens to $3.2M; revenues nil; FCGS trial begins

Ainos, Inc.

2024-Q2 EPS reported -$1.06 revenue$20,729

Revenues nil vs $28,555 YoY as COVID-19 test kit sales ceased; net loss $3,195,022 vs $2,349,727.
Cash $8,014,098 at June 30, 2024, after $9M convertible note in May and prepayment of senior secured note.
Enrolled first subject for VELDONA-based FCGS clinical study in July; 30-subject trial aims for Q1 2025 completion.
Next-Gen Ainos Flora VOC POCT with NVIDIA CUDA targets Q3 design completion, Q4 clinical trial kickoff.
Operating expenses rose to $3,023,636 from $2,289,336 YoY, driven by co-research, staff, and stock-based compensation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.